New Content  edit
Get The App!

An Interactive CME/CNE Certified Virtual Symposium

Holding Court in Pulmonary Hypertension: When Considering Escalation of Treatment, Does Delay in Escalation Beyond 3 Months Worsen Overall Prognosis?

An Interactive CME/CNE/CPE Certified Virtual Symposium


Sunday, October 17, 2021
12:45 - 1:45pm ET

Join the Live Event

This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians.

Symposium Overview

Court is in session! Holding Court in PH is an interactive webinar designed around a court case pro/con debate concept. Faculty act as the judge, attorneys, and witnesses, enabling the clinicians to present both sides of a controversial issue to allow the audience to fully understand the complexities of the issue. Using an integrated webinar polling system, you, the audience, serves as the jury and will vote to determine the final verdict.

Often clinicians are faced with the challenge of when to escalate care. This professional debate examines issues central to the question of whether PAH treatment should be advanced aggressively in cases where patients fail to show actual improvement, or whether treatment escalation can be safely delayed to possibly buy time for the patient. How will you vote based on the evidence presented?


Vallerie McLaughlin, MD - Judge

Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine Associate Chief of Cardiovascular Medicine Dept. of Internal Medicine/ Cardiovascular Medicine University of Michigan Ann Arbor, MI

Ioana Preston, MD - Attorney

Associate Professor of Medicine Tufts University School of Medicine Director, Pulmonary Hypertension Center Pulmonary, Critical Care and Sleep Division Tufts Medical Center Boston, MA

Richard Krasuski, MD – Attorney

Professor of Medicine and Pediatrics Director, Adult Congenital Heart Disease Center Director, Hemodynamic Research Director, Interventional CTEPH Program Duke University Medical Center Durham, NC

Sudarshan Rajagopal, MD, PhD - Witness

Associate Professor of Medicine Co-Director, Pulmonary Vascular Disease Center Duke University School of Medicine Durham, NC

Hunter Champion, MD, PhD, FAHA - Witness

Cardiologist Southeastern Cardiology Associates Columbus, GA

Full Accreditation and Program Information


12:45 pm
Welcome, Overview & Opening Scene: Introduction to the virtual courtroom concept & judge, prosecutor & defense opening remarks on the case topic
12:55 pm
Prosecutor examines witness & defense cross examines witness
1:10 pm
Defense attorney examines witness and prosecutor cross examines witness
1:25 pm
Attorney Closing arguments
1:35 pm
Judge concludes case and refers verdict determinization to the audience (jurors)
1:40 pm
Verdict is read with live Q.A to follow
1:45 pm

Target Audience

This activity has been designed to meet the educational needs of physicians, registered nurses, pharmacists and other healthcare professionals involved in the care of patients with pulmonary hypertension.

Learning Objectives

After completing this activity, the participant should be better able to:

  1. Review the risk assessment-based criteria used to determine the need for PAH treatment escalation
  2. Discuss the timing of periodic risk assessment in the PAH patient and whether this comes with a “one size fits all” strategy with respect to current goals of treatment
  3. Debate whether delaying treatment escalation buys time or is a formula for increasing PAH patient mortality/morbidity risk

Exclusive! Pre and Post-Meeting Content

Experience a new way to learn. Receive pre-meeting content and post-meeting quizzes to enhance your learning experience. Register now to access exclusive content and fully experience the benefits of this interactive program.

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Total CME.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live event for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.01 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-21-2998-L01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Fee Information: There is no fee for this educational activity.

Participants will receive an email after the event with a link to complete the evaluation form. Completion of the evaluation form will allow for credit to be processed and emailed to the participant.


Supported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson and United Therapeutics Corporation.

Jointly provided by TotalCME, Inc. & Postgraduate Institute for Medicine